Search research articles
Contact Us
Filters
Showing results (221-230 of 361) with videos related to
Page
of 37
Sort By:
Biorxiv : the Preprint Server for Biology
|
June 19, 2024
A prostate cancer gastrointestinal transcriptional phenotype may be associated with diminished response to AR-targeted therapy
Aishwarya Subramanian, Meng Zhang, Marina Sharifi, et al.
European Urology
|
September 24, 2024
Patient-reported Outcomes for Patients with Metastatic Castration-resistant Prostate Cancer and BRCA1/2 Gene Alterations: Final Analysis from the Randomized Phase 3 MAGNITUDE Trial
Dana E Rathkopf, Guilhem Roubaud, Kim N Chi, et al.
The Journal of Urology
|
August 28, 2012
Improved overall survival trends of men with newly diagnosed M1 prostate cancer: a SWOG phase III trial experience (S8494, S8894 and S9346)
Catherine M Tangen, Maha H A Hussain, Celestia S Higano, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 5, 2014
Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance)
Matthew R Smith, Susan Halabi, Charles J Ryan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 30, 2021
Predictive Biomarkers of Overall Survival in Patients with Metastatic Renal Cell Carcinoma Treated with IFNα ± Bevacizumab: Results from CALGB 90206 (Alliance)
Andrew B Nixon, Susan Halabi, Yingmiao Liu, et al.
European Journal of Cancer (Oxford, England : 1990)
|
October 2, 2018
Corrigendum to 'Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update' [Eur J Cancer 94 (May 2018) 115-125]
Toni K Choueiri, Colin Hessel, Susan Halabi, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 19, 2018
Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update
Toni K Choueiri, Colin Hessel, Susan Halabi, et al.
The New England Journal of Medicine
|
September 8, 2010
Sipuleucel-T immunotherapy for castration-resistant prostate cancer
Philip W Kantoff, Celestia S Higano, Neal D Shore, et al.
The Lancet. Oncology
|
September 15, 2018
Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the SPARTAN randomised, placebo-controlled, phase 3 trial
Fred Saad, David Cella, Ethan Basch, et al.
The Oncologist
|
March 29, 2022
COVID-19 Outcomes Among Patients With Cancer: Observations From the University of California Cancer Consortium COVID-19 Project Outcomes Registry
Hala T Borno, Mi-Ok Kim, Julian C Hong, et al.
Page
of 37
Search research articles
Search
Showing results (221-230 of 361) with videos related to
Sort By:
Page
of 37
Biorxiv : the Preprint Server for Biology
|
June 19, 2024
A prostate cancer gastrointestinal transcriptional phenotype may be associated with diminished response to AR-targeted therapy
Aishwarya Subramanian, Meng Zhang, Marina Sharifi, et al.
European Urology
|
September 24, 2024
Patient-reported Outcomes for Patients with Metastatic Castration-resistant Prostate Cancer and BRCA1/2 Gene Alterations: Final Analysis from the Randomized Phase 3 MAGNITUDE Trial
Dana E Rathkopf, Guilhem Roubaud, Kim N Chi, et al.
The Journal of Urology
|
August 28, 2012
Improved overall survival trends of men with newly diagnosed M1 prostate cancer: a SWOG phase III trial experience (S8494, S8894 and S9346)
Catherine M Tangen, Maha H A Hussain, Celestia S Higano, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 5, 2014
Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance)
Matthew R Smith, Susan Halabi, Charles J Ryan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 30, 2021
Predictive Biomarkers of Overall Survival in Patients with Metastatic Renal Cell Carcinoma Treated with IFNα ± Bevacizumab: Results from CALGB 90206 (Alliance)
Andrew B Nixon, Susan Halabi, Yingmiao Liu, et al.
European Journal of Cancer (Oxford, England : 1990)
|
October 2, 2018
Corrigendum to 'Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update' [Eur J Cancer 94 (May 2018) 115-125]
Toni K Choueiri, Colin Hessel, Susan Halabi, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 19, 2018
Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update
Toni K Choueiri, Colin Hessel, Susan Halabi, et al.
The New England Journal of Medicine
|
September 8, 2010
Sipuleucel-T immunotherapy for castration-resistant prostate cancer
Philip W Kantoff, Celestia S Higano, Neal D Shore, et al.
The Lancet. Oncology
|
September 15, 2018
Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the SPARTAN randomised, placebo-controlled, phase 3 trial
Fred Saad, David Cella, Ethan Basch, et al.
The Oncologist
|
March 29, 2022
COVID-19 Outcomes Among Patients With Cancer: Observations From the University of California Cancer Consortium COVID-19 Project Outcomes Registry
Hala T Borno, Mi-Ok Kim, Julian C Hong, et al.
Page
of 37